Zhou Zheng, Dai Cong, Liu Wei-xin
Hepatogastroenterology. 2015 Jun;62(140):829-37.
BACKGROUND/AIMS: TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with con- ventional therapy.
The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.
Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR =1.82; 95% CI 1.24 to 2.67) and clinical response (RR =1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.
Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.
背景/目的：肿瘤坏死因子-α（TNF-α）在溃疡性结肠炎（UC）的发病机制中起重要作用。抗TNF-α治疗似乎对UC治疗有益。目的是评估英夫利昔单抗和阿达木单抗与传统疗法相比治疗UC的有效性。
检索了PubMed和Embase数据库中研究英夫利昔单抗和阿达木单抗治疗UC疗效的研究。
与传统疗法相比，英夫利昔单抗在诱导UC临床缓解（RR = 1.67；95%CI 1.12至2.50）方面有统计学显著效果，但在临床缓解（RR = 1.63；95%CI 0.84至3.18）和降低UC结肠切除术率（RR = 0.54；95%CI 0.26至1.12）方面无统计学显著效果。与传统疗法相比，阿达木单抗在诱导UC临床缓解（RR = 1.82；95%CI 1.24至2.67）和临床缓解（RR = 1.36；95%CI 1.13至1.64）方面有统计学显著效果。
我们的荟萃分析表明，与传统疗法相比，英夫利昔单抗在诱导UC临床缓解方面有统计学显著效果，阿达木单抗在诱导UC临床缓解和临床缓解方面与传统疗法相比有统计学显著效果。
